Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

This phase I trial finds out the best dose, possible benefits and/or side effects of papaverine when given together with chemoradiation intreating patients with stage II-III non-small cell lung cancer. Papaverine targets mitochondrial metabolism to decrease the cancer growth process. Giving papaverine with chemoradiation may work best to treat patients with non-small cell lung cancer.

Trial Details

NCT ID
NCT05136846
Phase
PHASE1
Sponsor
Ohio State University Comprehensive Cancer Center
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Carboplatin
  • Durvalumab
  • Paclitaxel
  • Papaverine
  • Radiation Therapy
  • Pemetrexed
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

  • All prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0) =\< grade 1 (except alopecia) a…
  • Absolute neutrophil count \>=1.5 x 10\^9/L
  • Hemoglobin \>= 9 g/dL
  • Platelets \>= 100 x 10\^9/L

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →